The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

It's worth noting that Biohaven has just reported that sales of Nurtec ODT came in at $124 million in the first quarter – below analyst projections and the $190 million made in the last quarter ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

Nurtec ODT (rimegepant) is a prescription drug that treats and helps prevent migraine episodes. It works by blocking a certain protein in the brain and nervous system that can cause migraine. CGRP ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease. The FDA’s Decision on BHVN’s Drug Candidate The FDA agreed to review BHVN ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed ...

In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks with heavy insider buying in 2025. Insider trading is often seen as an important ...

Approval could come rather soon. Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once ...

Biohaven has a 52-week low of $26.80 and a 52-week high of $62.21. Biohaven ( NYSE:BHVN – Get Free Report ) last announced its earnings results on Monday, March 3rd.

Shares of BHVN opened at $29.87 on Wednesday. Biohaven has a 1-year low of $26.80 and a 1-year high of $62.21. The stock has a market cap of $3.02 billion, a PE ratio of -3.19 and a beta of 1.27 ...